SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001576885-24-000009
Filing Date
2024-01-04
Accepted
2024-01-04 16:18:22
Documents
4
Period of Report
2024-01-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1704403087.html 4  
1 FORM 4 wk-form4_1704403087.xml 4 5804
2 EX-24.1 active_136271245x2xacume.htm EX-24.1 3955
3 active_136271245x2xacume001.jpg GRAPHIC 193554
4 active_136271245x2xacume002.jpg GRAPHIC 37239
  Complete submission text file 0001576885-24-000009.txt   329254
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902
Business Address
OConnell Daniel Joseph (Reporting) CIK: 0001865136 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40551 | Film No.: 24512165